ESSA Pharma Inc. Common Stock
EPIX Real Time Price USDRecent trades of EPIX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by EPIX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof Oct. 08, 2024
-
Patent Title: Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof Nov. 14, 2023
-
Patent Title: Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof Dec. 06, 2022
-
Patent Title: Androgen receptor modulators and methods for their use Nov. 01, 2022
-
Patent Title: Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof Jun. 14, 2022
-
Patent Title: Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof Feb. 08, 2022
-
Patent Title: Androgen receptor modulators and methods for their use Jul. 13, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of EPIX in WallStreetBets Daily Discussion
Recent insights relating to EPIX
Recent picks made for EPIX stock on CNBC
ETFs with the largest estimated holdings in EPIX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view EPIX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.